Multiple Myeloma Cell Therapy Market Size Worth $25.7 billion in 2021 with the Highest Contribution from North America – GlobalData Plc
The multiple myeloma cell therapy market was valued at $25.7 billion in 2021. Multiple myeloma is a heterogeneous disease, characterized by the aberrant proliferation of plasma cells and subsequent overproduction of monoclonal paraprotein (M protein). a variety of factors, including genetics, environmental and occupational exposure to carcinogens, exposure to radiation, chronic inflammatory state, and infection, are hypothesized to contribute to the causing of this disease. In multiple myeloma, protein levels are routinely used to diagnose and monitor disease progression.
This report includes both cell therapies and established/traditional MM therapies. The 15 markets comprise the 8MM and seven countries known to have increased potential for cell therapies given the current drug development landscape including Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada.
For more insights on the multiple myeloma cell therapy market outlook, read our free sample report
Multiple Myeloma Cell Therapy Market FAQs
- What was the multiple myeloma cell therapy market size in 2021?
The multiple myeloma cell therapy market was valued at $25.7 billion in 2021.
- What are the key regions in the multiple myeloma cell therapy market?
The key regions in the multiple myeloma cell therapy market are North America, Europe, Middle East, and APAC.
- Which region dominated the multiple myeloma cell therapy market?
North America dominated the multiple myeloma cell therapy market.
- Who are the leading multiple myeloma cell therapy market players?
Celgene Corp, Johnson & Johnson, Chongqing Precision Biotech Co Ltd, Shangai Changzheng Hospital, and MediGene AG are some of the leading multiple myeloma cell therapy market players.
- Which player dominated the multiple myeloma cell therapy market?
Celgene Corp dominated the multiple myeloma cell therapy market in 2021.
For more queries on the multiple myeloma cell therapy market,
download a sample now!
Multiple Myeloma Cell Therapy Market Dynamics
The multiple myeloma cell therapy market is mainly driven by the approval of autologous CAR-T cell therapies including Abecma and Carvykti. CAR-Ts’ success in MM has fueled R&D investment into this therapy class, with more CAR-Ts in development than all other cell and gene therapy (cell therapy) classes combined.
The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, multiple allogeneic CAR-Ts are in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies. Bristol-Myers Squibb’s Abecma is the only marketed cell therapy product in MM as of 2021. However, pipeline cell therapies will face significant competition from marketed CAR-Ts, and are unlikely to gain large market share due to the lack of novel antigens and mechanisms of action (MoAs), as well as comparative clinical trial data. In addition, patients may prefer more convenient therapies which do not require IV administration.
Multiple Myeloma Cell Therapy Market Regional Outlook
The key regions in the MM market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021. The 15 Markets comprise the 8MM and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, Canada.
For additional information on the multiple myeloma cell therapy market impact on each region, get a free sample PDF
Multiple Myeloma Cell Therapy Market – Leading Players
Some of the future players in the MM market are Celgene Corp, Johnson & Johnson, Chongqing Precision Biotech Co Ltd, Shangai Changzheng Hospital, and MediGene AG, among others. Celgene Corp has the highest number of products in ongoing clinical trials and development phases. Leading MM players, such as Johnson & Johnson and Bristol Myers Squibb, are all looking to bolster their positions as market leaders by entering their cell therapies into trials for earlier-stage settings.
Know more about each contributing player as you grab your sample report copy!
Key Segments Covered in the Report
Multiple Myeloma Cell Therapy Regional Outlook (Value, $Billion, 2021-2031)
- North America
- Middle East
Get more insights and detailed market scope in the report PDF sample
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Mycosis Fungoides Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update
Chronic Lymphocytic Leukemia (CLL) Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
Table of Contents
1.2. Report Scope
- Executive Summary
- Disease Overview
3.1. MM Etiology & Staging
3.2. Treatment Algorithm
- Marketed & Pipeline Drugs Overview
4.1. Marketed Drugs Overview
4.2. Pipeline Analysis
4.3. Target Analysis and Clinical Benchmarks
- Market Outlook
5.1. 10-Year Market Analysis with Drivers and Barriers
5.2. 10-Year Market Outlook – 15 Markets
- Unmet Needs
- Likelihood of Approval Analysis and Phase Transition Success Rate Analysis
- Competitive Assessment
8.1. Competitive Analysis by Class of Therapy
- Future Players
9.1. Future Players Based on Pipeline Strength
GlobalData is a leading provider of data, analytics, and insights on the world’s largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision-makers to predict and navigate the future. GlobalData’s mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on us for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Head of PR EMEA
+44 (0)207 936 6400
Media Contacts GlobalData Mark Jephcott Head of PR EMEA firstname.lastname@example.org cc: email@example.com +44 (0)207 936 6400
Reportedtimes, Extended Distribution, iCN Internal Distribution, Research Newswire, English